Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully-integrated biopharmaceutical company with commercial products and a robust development pipeline, will ...

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on ...

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.75%, which has investors questioning if this is right ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 18.09%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Stock analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Tonix Pharmaceuticals in a report released on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz anticipates that ...

CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development ...

On March 24, 2025, Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) announced that the FDA will not require an Advisory Committee (AdCom) meeting regarding the New Drug Application (NDA) for TNX-102 SL ...